Results 21 to 30 of about 2,468 (182)
Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal
Therapeutics and Clinical Risk Management, 2018 Marco Proietti,1–3 Giuseppe Boriani4 1Department of Neuroscience, IRCCS – Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy; 2Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK ...
Proietti M, Boriani G
doaj +1 more source
Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage [PDF]
Clinical Practice and Cases in Emergency Medicine, 2017 Dabigatran etexilate mesylate is a direct thrombin inhibitor used for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Jonathan Balakumar +2 more
doaj +2 more sources
Vascular Health and Risk Management, 2016 Tiffany Y Hu,1 Vaibhav R Vaidya,2 Samuel J Asirvatham2,31Mayo Medical School, 2Division of Cardiovascular Diseases, Department of Internal Medicine, 3Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, MN, USAAbstract: Novel oral ...
Vaibhav Vaidya, Tiffany Hu
exaly +2 more sources
Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
Trauma Case Reports, 2021 Dabigatran is an oral anticoagulant directly acting as thrombin inhibitor. The monoclonal antibody idarucizumab was developed to reverse its anticoagulatory effects after application of a standardized dose.
Mathias Ströhle +4 more
doaj +1 more source
The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation
Scientific Reports, 2021 Dabigatran interferes with many coagulation tests. To overcome this obstacle the use of idarucizumab as an in vitro antidote to dabigatran has been proposed.
Mojca Božič Mijovski +4 more
doaj +1 more source
Medicina, 2023 Background and Objectives: The effectiveness and safety of idarucizumab for the reversal of the effects of dabigatran have been proven. However, there remains a paucity of literature comprehensively investigating outcomes in real-world patients.
Jhih-Wei Dai +3 more
doaj +1 more source
Clinical and Applied Thrombosis/Hemostasis, 2022 Purpose: To assess costs and healthcare resource utilization (HCRU) associated with the use of idarucizumab for the reversal of dabigatran and andexanet alfa for the reversal of direct oral Factor Xa inhibitors.
Alex C. Spyropoulos MD +6 more
doaj +1 more source
Dabigatran-idarucizumab pharmacokinetics-pharmacodynamics in sheep undergoing cardiopulmonary bypass. [PDF]
PerfusionBackgroundThe effect of the anticoagulant, dabigatran, and its antagonist, idarucizumab, on coagulation remains poorly quantified. There are few pharmacokinetic-pharmacodynamic data available to describe the interaction in humans or animals undergoing ...
Eaton MP +3 more
europepmc +2 more sources
Cardiology and Therapy, 2020 Introduction Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran, and it was approved in Japan in September 2016.
Masahiro Yasaka +7 more
doaj +1 more source
Retrospective Observational Study of Patients With Subdural Hematoma Treated With Idarucizumab
Neurotrauma Reports, 2023 Use of anticoagulants is increasing with the aging of societies. The safe first-line drug is likely to be a direct oral anticoagulant (DOAC), but outcomes of treatment of traumatic brain injury (TBI) with anticoagulants are uncertain.
Eiichi Suehiro +24 more
doaj +1 more source